You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tislelizumab

Showing 1 - 25 of 200
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer Trial (HAIC, Surufatinib, Tislelizumab)

Not yet recruiting
  • Carcinoma
  • +7 more
  • (no location specified)
Nov 12, 2023

Tislelizumab Combined With Chemotherapy in First-line Treatment

Active, not recruiting
  • Tislelizumab
  • +3 more
  • Tislelizumab
  • Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Sep 6, 2023

Colonic Tumors, Neoadjuvant Therapy, Immune Checkpoint Inhibitors Trial in Nanning (Tislelizumab, Oxaliplatin, Capecitabine)

Recruiting
  • Colonic Neoplasms
  • +2 more
  • Tislelizumab
  • +3 more
  • Nanning, Guangxi, China
    The First Affiliated Hospital of Guangxi Medical University
Nov 9, 2023

Solid Tumor, Adult Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)

Recruiting
  • Solid Tumor, Adult
  • Tislelizumab
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 13, 2023

Extensive Stage Small Cell Lung Cancer Trial in Hangzhou (Tislelizumab, Anlotinib)

Recruiting
  • Extensive Stage Small Cell Lung Cancer
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Jun 6, 2023

Resectable Hepatocellular Carcinoma Trial (Tislelizumab, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • Tislelizumab
  • Tislelizumab, Lenvatinib
  • (no location specified)
Mar 29, 2023

Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)

Not yet recruiting
  • Gastric
  • Colorectal Adenocarcinoma
  • tislelizumab
  • Shenyang, Liaoning, China
    Liaoning Cancer Hospital & Institute
Nov 1, 2023

Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy Trial in Shanghai (Tislelizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Tislelizumab
  • Shanghai, Shanghai, China
    Shanghai chest hospital
Sep 24, 2023

Hepatocellular Carcinoma Trial (Cryoablation, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Cryoablation
  • +2 more
  • (no location specified)
May 31, 2023

Advanced Solid Tumor, Solid Tumor Trial (BGB-26808, Tislelizumab)

Not yet recruiting
  • Advanced Solid Tumor
  • Solid Tumor
  • (no location specified)
Aug 7, 2023

Esophageal Squamous Cell Carcinoma Trial in Shantou (Tislelizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Tislelizumab
  • Shantou, Guangdong, China
    Cancer Hospital of Shantou University Medical College
Aug 2, 2023

MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin Trial (Tislelizumab)

Not yet recruiting
  • MSI-H Colorectal Cancer
  • +3 more
  • Tislelizumab
  • (no location specified)
Apr 23, 2023

Gastric Cancer Metastatic to Liver Trial in Shanghai (Cryoablation, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Gastric Cancer Metastatic to Liver
  • Cryoablation
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 6, 2023

Non-Muscle Invasive Bladder Cancer, HER2 Trial (RC48, Tislelizumab)

Not yet recruiting
  • Non-Muscle Invasive Bladder Cancer
  • HER2
  • (no location specified)
Jul 16, 2023

Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage Trial (LBL-007,

Not yet recruiting
  • Esophageal Cancer
  • +2 more
  • (no location specified)
Aug 21, 2023

Advanced Biliary Tract Cancer Trial (H101, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Advanced Biliary Tract Cancer
  • (no location specified)
Apr 11, 2023

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer Trial (Tislelizumab, BGB-A425, LBL-007)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Head and Neck Cancer
  • Tislelizumab
  • +2 more
  • (no location specified)
Jun 9, 2023

Fumarate Hydratase Deficient Renal Cell Carcinoma Trial (Tislelizumab, Lenvatinib)

Not yet recruiting
  • Fumarate Hydratase Deficient Renal Cell Carcinoma
  • (no location specified)
May 18, 2023

Gastric Cancer Trial (Tislelizumab, 5Fu, Paclitaxel injection)

Not yet recruiting
  • Gastric Cancer
  • Tislelizumab
  • +2 more
  • (no location specified)
Feb 21, 2023

Biliary Tract Carcinoma Trial in Beijing (Gemcitabine, S1, Tislelizumab)

Not yet recruiting
  • Biliary Tract Carcinoma
  • Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Apr 10, 2023

Esophageal Squamous Cell Carcinoma Trial in Wuhan (Intensity-modulated radiotherapy (IMRT), Tislelizumab, Cisplatin)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Intensity-modulated radiotherapy (IMRT)
  • +3 more
  • Wuhan, Hubei, China
    Renmin hosptial of Wuhan University
Jun 16, 2023

Colorectal Cancer Trial (Tislelizumab, Irinotecan Hydrochloride, cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Tislelizumab
  • +3 more
  • (no location specified)
Mar 23, 2023

Pancreatic Cancer Trial in New York (Canakinumab, Tislelizumab, Nab-Paclitaxel)

Recruiting
  • Pancreatic Cancer
  • New York, New York
  • +2 more
Aug 2, 2023

Colorectal Liver Metastases Trial in Beijing (Tislelizumab, Regorafenib, HAIC)

Recruiting
  • Colorectal Liver Metastases
  • Tislelizumab
  • +2 more
  • Beijing, Beijing, China
  • +1 more
May 25, 2023

Oral Squamous Cell Carcinoma Trial (Tislelizumab, Albumin paclitaxel, Cisplatin)

Not yet recruiting
  • Oral Squamous Cell Carcinoma
  • Tislelizumab
  • +3 more
  • (no location specified)
May 7, 2023